Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreichs Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting…
